Format
Sort by
Items per page

Send to

Choose Destination

Best matches for JC polyomavirus multiple sclerosis:

Update on disease-modifying therapies for multiple sclerosis. Vargas DL et al. J Investig Med. (2017)

Natalizumab in Multiple Sclerosis: Long-Term Management. Clerico M et al. Int J Mol Sci. (2017)

The biology of JC polyomavirus. Assetta B et al. Biol Chem. (2017)

Search results

Items: 1 to 20 of 430

1.

The spectrum of progressive multifocal leukoencephalopathy: A practical approach.

Bartsch T, Rempe T, Leypoldt F, Riedel C, Jansen O, Berg D, Deuschl G.

Eur J Neurol. 2019 Jan 10. doi: 10.1111/ene.13906. [Epub ahead of print]

PMID:
30629326
2.

Impact of Disease-Modifying Treatments on the Longitudinal Evolution of Anti-JCV Antibody Index in Multiple Sclerosis.

Hegen H, Walde J, Bsteh G, Auer M, Wurth S, Zinganell A, Di Pauli F, Deisenhammer F, Berger T.

Front Immunol. 2018 Oct 25;9:2435. doi: 10.3389/fimmu.2018.02435. eCollection 2018.

3.

Seroconversion of JCV antibodies is strongly associated to natalizumab therapy.

Fragoso YD, Brooks JBB, Eboni ACB, Fezer L, da Gama PD, Gomes S, Gonçalves MVM, Machado SN, Morales RR, Pimentel MLV, Ruocco HH, Santos GA, Scherpenhuijzen S, Sousa NAC.

J Clin Neurosci. 2018 Nov 3. pii: S0967-5868(18)31082-8. doi: 10.1016/j.jocn.2018.10.128. [Epub ahead of print]

PMID:
30396814
4.

Early diagnosis of progressive multifocal leucoencephalopathy: longitudinal lesion evolution.

Scarpazza C, Signori A, Prosperini L, Sormani MP, Cosottini M, Capra R, Gerevini S; Italian PML Group.

J Neurol Neurosurg Psychiatry. 2018 Nov 2. pii: jnnp-2018-319208. doi: 10.1136/jnnp-2018-319208. [Epub ahead of print]

PMID:
30389778
5.

Anti-JC virus antibody index changes in rituximab-treated multiple sclerosis patients.

Baber U, Bouley A, Egnor E, Sloane JA.

J Neurol. 2018 Oct;265(10):2342-2345. doi: 10.1007/s00415-018-8996-3. Epub 2018 Aug 14.

PMID:
30109480
6.

Performance of PML diagnostic criteria in natalizumab-associated PML: data from the Dutch-Belgian cohort.

Wijburg MT, Warnke C, Barkhof F, Uitdehaag BMJ, Killestein J, Wattjes MP.

J Neurol Neurosurg Psychiatry. 2019 Jan;90(1):44-46. doi: 10.1136/jnnp-2018-318261. Epub 2018 Aug 12.

PMID:
30100552
7.

[MRI alterations in immunomodulation].

Guggenberger K, Urbach H.

Nervenarzt. 2018 Aug;89(8):945-957. doi: 10.1007/s00115-018-0565-6. German.

PMID:
30030575
8.

Detection of JC virus archetype in cerebrospinal fluid in a MS patient with dimethylfumarate treatment without lymphopenia or signs of PML.

Motte J, Kneiphof J, Straßburger-Krogias K, Klasing A, Adams O, Haghikia A, Gold R.

J Neurol. 2018 Aug;265(8):1880-1882. doi: 10.1007/s00415-018-8931-7. Epub 2018 Jun 15.

PMID:
29948248
9.

Cost-minimization analysis of alemtuzumab compared to fingolimod and natalizumab for the treatment of active relapsing-remitting multiple sclerosis in the Netherlands.

Piena MA, Heisen M, Wormhoudt LW, Wingerden JV, Frequin STFM, Uitdehaag BMJ.

J Med Econ. 2018 Oct;21(10):968-976. doi: 10.1080/13696998.2018.1489255. Epub 2018 Jul 9.

PMID:
29911917
10.

Anti-JC virus antibody sera positivity and index value among patients with multiple sclerosis may be correlated with age, sex, and area of residence.

Koolaji S, Allahabadi NS, Ahmadi A, Eskandarieh S, Moghadasi AN, Azimi AR, Sahraian MA.

J Neurovirol. 2018 Oct;24(5):570-576. doi: 10.1007/s13365-018-0646-0. Epub 2018 May 21.

PMID:
29785581
11.

Aging and lymphocyte changes by immunomodulatory therapies impact PML risk in multiple sclerosis patients.

Mills EA, Mao-Draayer Y.

Mult Scler. 2018 Jul;24(8):1014-1022. doi: 10.1177/1352458518775550. Epub 2018 May 18.

PMID:
29774781
12.

Progression of a series of patients with relapsing-remitting multiple sclerosis treated for 7 years with natalizumab using the "no evidence of disease activity" parameter.

Pato Pato A, Costa Arpín E, Rodríguez Regal A, Rodríguez Constenla I, Cimas Hernando I, Muñoz Pousa I, Naya Ríos L, Lorenzo González JR, Amigo Jorrín MC, Prieto González JM.

Neurologia. 2018 May 10. pii: S0213-4853(18)30083-5. doi: 10.1016/j.nrl.2018.02.003. [Epub ahead of print] English, Spanish.

13.

Fingolimod-associated PML with mild IRIS in MS: A clinicopathologic study.

Nishiyama S, Misu T, Shishido-Hara Y, Nakamichi K, Saijo M, Takai Y, Takei K, Yamamoto N, Kuroda H, Saito R, Watanabe M, Tominaga T, Nakashima I, Fujihara K, Aoki M.

Neurol Neuroimmunol Neuroinflamm. 2017 Nov 10;5(1):e415. doi: 10.1212/NXI.0000000000000415. eCollection 2018 Jan.

14.

Editors' Welcome: Pregnancy and progressive multifocal leukoencephalopathy.

Levy M, Giovannoni G, Hawkes C, Waubant E.

Mult Scler Relat Disord. 2018 Apr;21:A1-A2. doi: 10.1016/j.msard.2018.03.016. No abstract available.

PMID:
29724377
15.

JC Virus-DNA Detection Is Associated with CD8 Effector Accumulation in Peripheral Blood of Patients with Multiple Sclerosis under Natalizumab Treatment, Independently from JC Virus Serostatus.

Zingaropoli MA, Iannetta M, Pontecorvo S, Anzivino E, Prezioso C, Rodio DM, Morreale M, D'Abramo A, Oliva A, Lichtner M, Cortese A, Frontoni M, Pietropaolo V, Francia A, Mastroianni CM, Vullo V, Ciardi MR.

Biomed Res Int. 2018 Feb 27;2018:5297980. doi: 10.1155/2018/5297980. eCollection 2018.

16.

New biological agents in the treatment of multiple sclerosis.

Buc M.

Bratisl Lek Listy. 2018;119(4):191-197. doi: 10.4149/BLL_2018_035. Review.

PMID:
29663814
17.

Pathogenesis of progressive multifocal leukoencephalopathy and risks associated with treatments for multiple sclerosis: a decade of lessons learned.

Major EO, Yousry TA, Clifford DB.

Lancet Neurol. 2018 May;17(5):467-480. doi: 10.1016/S1474-4422(18)30040-1. Review.

PMID:
29656742
18.

John Cunningham virus: an overview on biology and disease of the etiological agent of the progressive multifocal leukoencephalopathy.

Pietropaolo V, Prezioso C, Bagnato F, Antonelli G.

New Microbiol. 2018 Jul;41(3):179-186. Epub 2018 Apr 5. Review.

19.

Serum anti-JCV antibody indexes in Japanese patients with multiple sclerosis: elevations along with fingolimod treatment duration.

Aoyama S, Mori M, Uzawa A, Uchida T, Masuda H, Ohtani R, Kuwabara S.

J Neurol. 2018 May;265(5):1145-1150. doi: 10.1007/s00415-018-8813-z. Epub 2018 Mar 12.

PMID:
29532286
20.

Association of Progressive Multifocal Leukoencephalopathy Lesion Volume With JC Virus Polymerase Chain Reaction Results in Cerebrospinal Fluid of Natalizumab-Treated Patients With Multiple Sclerosis.

Wijburg MT, Kleerekooper I, Lissenberg-Witte BI, de Vos M, Warnke C, Uitdehaag BMJ, Barkhof F, Killestein J, Wattjes MP.

JAMA Neurol. 2018 Jul 1;75(7):827-833. doi: 10.1001/jamaneurol.2018.0094.

PMID:
29532061

Supplemental Content

Loading ...
Support Center